12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BI 1034020: Phase I started

Boehringer began a single-blind, placebo-controlled, German Phase I trial evaluating single ascending-doses of IV and subcutaneous BI 1034020 in 80 healthy volunteers. The start of the trial triggered a €5 million ($6.9 million) to Ablynx...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >